Last reviewed · How we verify
NCT03049774
A Retrospective Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
trial in Chemotherapy-induced Thrombocytopenia in 2,000 participants. Status unknown.
1 August 2017
Quick facts
| Lead sponsor | Angde Biotech Pharmaceutical Co., Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 28 February 2017 |
| Primary completion | 1 August 2017 |
| Estimated completion | 1 December 2017 |
| Sites | 1 location across China |
Conditions studied
- Chemotherapy-induced Thrombocytopenia — all drugs for Chemotherapy-induced Thrombocytopenia →
Sponsor
Angde Biotech Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 85, any sex, with Chemotherapy-induced Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Days that platelet count firstly rebound to 75×10^9/L, 100×10^9/L, respectively, from the first time below 75×10^9/L at the chemotherapy cycle and the last chemotherapy cycle
Time frame: 56 days
For prevention -
Days that platelet count firstly rebound to 75×10^9/L, 100×10^9/L
Time frame: 28 days after the administration of Baijieyi
For treatment
Sponsor's own description
The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include May 8th of 2008 to december 31st of 2016.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03049774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy-induced Thrombocytopenia
Currently open trials in the same condition.
- NCT05236582 — Herombopag for Chemotherapy-induced Thrombocytopenia · Phase 2 · recruiting
- NCT05218226 — Avatrombopag for Chemotherapy-induced Thrombocytopenia · Phase 2 · recruiting
- NCT04600960 — Eltrombopag for Chemotherapy-induced Thrombocytopenia · Phase 2 · recruiting
- NCT03937154 — Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) · Phase 3 · active not recruiting
Other Angde Biotech Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT05629598 — A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia . · Phase 2 · unknown
- NCT05295173 — A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） · Phase 3 · completed
- NCT04028518 — A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke. · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03049774 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Angde Biotech Pharmaceutical Co., Ltd.
- Last refreshed: 8 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03049774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing